OPS
TERN

Orion Portfolio Solutions’s Terns Pharmaceuticals TERN Stock Holding History

Orion Portfolio Solutions’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,211
Closed -$123K – 1978
2024
Q4 		$123K Buy
+22,211
New +$150K ﹤0.01% 1784

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Orion Portfolio Solutions's TERN Position: Q1 2025 in Review

Orion Portfolio Solutions sold out of Terns Pharmaceuticals (TERN) in Q1 2025, closing a stake of 22,211 shares — an estimated $123K sold.

Orion Portfolio Solutions first reported a position in TERN in Q4 2024 and held it in 1 quarter. The position peaked at $123K in Q4 2024. 137 funds tracked by Wall St. Rank hold TERN as of Q1 2025.

  • Orion Portfolio Solutions reported no remaining Terns Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Orion Portfolio Solutions sold 22,211 Terns Pharmaceuticals shares in Q1 2025, an estimated $123K.
  • Orion Portfolio Solutions first reported a position in Terns Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Orion Portfolio Solutions's Terns Pharmaceuticals position peaked at $123K in Q4 2024.
  • 137 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2025.

Based on Orion Portfolio Solutions's 13F filing for Q1 2025, filed 14 May 2025.